Cite
HARVARD Citation
Mancinelli, C. et al. (2021). Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab. Multiple sclerosis. pp. 790-794. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Mancinelli, C. et al. (2021). Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab. Multiple sclerosis. pp. 790-794. [Online].